Edmonston_NP Measles_NP Virus_NP Prevents_NP Increased_VBD Cell_NP Surface_NP Expression_NP of_IN Peptide-Loaded_NP Major_NP Histocompatibility_NN Complex_NP Class_NP II_NP Proteins_NPS in_IN Human_NP Peripheral_NP Monocytes_NP Gamma_NP interferon_NN (_( IFN-gamma_NP )_) induces_VBZ expression_NN of_IN the_DT gene_NN products_NNS of_IN the_DT major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) ,_, whereas_IN IFN-alpha/beta_NP can_MD interfere_VB with_IN or_CC suppress_VB class_NN II_NP protein_NN expression_NN ._SENT In_IN separate_JJ studies_NNS ,_, measles_NN virus_NN (_( MV_NP )_) was_VBD reported_VBN to_TO induce_VB IFN-alpha/beta_NP and_CC to_TO up-regulate_JJ MHC_NP class_NN II_NP proteins_VBZ ._SENT In_IN an_DT attempt_NN to_TO resolve_VB this_DT paradox_NN ,_, we_PP examined_VBD the_DT surface_NN expression_NN of_IN MHC_NP class_NN I_PP and_CC class_VB II_NP proteins_NNS in_IN MV-infected_JJ peripheral_JJ monocytes_NNS in_IN the_DT presence_NN and_CC absence_NN of_IN IFN-alpha/beta_NP ._SENT Infection_NN of_IN purified_VBN monocytes_NNS with_IN Edmonston_NP B_NP MV_NP resulted_VBD in_IN an_DT apparent_JJ increase_NN in_IN cell_NN surface_NN expression_NN of_IN HLA-A_NP ,_, -B_NN ,_, and_CC -C_NN class_NN I_PP proteins_VBZ ,_, but_CC it_PP had_VBD no_DT effect_NN on_IN the_DT expression_NN of_IN HLA-DR_NP class_NN II_NP proteins_VBZ ._SENT MV-infected_NP purified_VBD monocytes_NNS expressed_VBD IFN-alpha/beta_NP ,_, but_CC no_DT measurable_JJ IFN-gamma_NP expression_NN was_VBD detected_VBN in_IN supernatant_JJ fluids_NNS ._SENT Class_NP II_NP protein_NN expression_NN could_MD be_VB enhanced_VBN by_IN coculture_NN of_IN purified_VBN monocytes_NNS with_IN uninfected_JJ peripheral_JJ blood_NN mononuclear_JJ cell_NN (_( PBMC_NP )_) supernatant_JJ ._SENT MV_NP infection_NN of_IN PBMCs_NP also_RB did_VBD not_RB affect_VB expression_NN of_IN class_NN II_CD proteins_NNS ,_, but_CC the_DT expression_NN of_IN HLA-A_NP ,_, -B_NN ,_, and_CC -C_NN class_NN I_PP proteins_VBZ was_VBD increased_VBN two-_NN to_TO threefold_JJ in_IN most_JJS donor_NN cells_NNS ._SENT A_DT direct_JJ role_NN for_IN IFN-alpha/beta_NP suppression_NN of_IN MHC_NP class_NN II_NP protein_NN expression_NN was_VBD not_RB evident_JJ in_IN monocytes_NNS since_IN MV_NP suppressed_VBD class_NN II_NP protein_NN expression_NN in_IN the_DT absence_NN of_IN IFN-alpha/beta_NP ._SENT Taken_VBN together_RB ,_, these_DT data_NNS suggest_VBP that_IN MV_NP interferes_VBZ with_IN the_DT expression_NN of_IN peptide-loaded_JJ class_NN II_NP complexes_NNS ,_, an_DT effect_NN that_WDT may_MD potentially_RB alter_VB CD4+-T-cell_NN proliferation_NN and_CC the_DT cell-mediated_JJ immune_JJ responses_NNS that_IN they_PP help_VBP to_TO regulate_VB ._SENT Measles_NN virus_NN (_( MV_NP )_) is_VBZ an_DT immunosuppressive_JJ virus_NN that_WDT can_MD mediate_VB profound_JJ transient_JJ suppression_NN of_IN a_DT wide_JJ array_NN of_IN immune_JJ responses_NNS ._SENT These_DT include_VBP decreased_VBN in_IN vitro_NP proliferative_JJ responses_NNS to_TO mitogens_NNS and_CC MV_NP antigens_NNS ,_, lymphopenia_NN ,_, decreased_VBD natural_JJ killer_NN (_( NK_JJ )_) cell_NN activity_NN ,_, increased_VBD plasma_NN immunoglobulin_NN E_NP (_( IgE_NP )_) ,_, and_CC alterations_NNS in_IN cytokine_NN production_NN ._SENT The_DT virus_NN is_VBZ localized_VBN to_TO monocytes/macrophages_NNS in_IN infected_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) ._SENT Monocyte/macrophage_NN activation_NN represents_VBZ a_DT key_JJ step_NN in_IN the_DT clearance_NN of_IN many_JJ virus_NN infections_NNS ._SENT Once_RB activated_VBN ,_, monocytes/macrophages_NNS rapidly_RB produce_VBP cytokines_NNS (_( e.g._FW ,_, alpha/beta_JJ interferon_NN [_SYM IFN-alpha/beta_NP ]_SYM and_CC tumor_NN necrosis_NN factor_NN alpha_NN )_) and_CC nitric_JJ oxide_NN ,_, which_WDT have_VBP direct_JJ antiviral_JJ activity_NN ._SENT Monocytes_NNS have_VBP a_DT significant_JJ role_NN in_IN the_DT immune_JJ response_NN to_TO virus_NN infection_NN in_IN part_NN because_IN they_PP express_VBP major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_NN I_PP and_CC class_VB II_NP proteins_NNS on_IN their_PP$ cell_NN surfaces_NNS ._SENT Class_NN I_PP and_CC class_VB II_NP proteins_NNS are_VBP critical_JJ to_TO the_DT presentation_NN of_IN virus-derived_JJ antigens_NNS to_TO CD8+_NP and_CC CD4+_NP T_NN cells_NNS ,_, respectively_RB ._SENT Viral-antigen_NN presentation_NN to_TO CD8+_NP T_NN cells_NNS is_VBZ mediated_VBN by_IN MHC_NP class_NN I_PP complexes_NNS of_IN heavy_JJ chain_NN and_CC beta2-microglobulin_NN ,_, together_RB with_IN antigenic_JJ peptides_NNS derived_VBN from_IN processed_JJ virus_NN proteins_NNS ._SENT Class_NP I_NP complexes_NNS alert_VB cytotoxic_JJ T_NN cells_NNS to_TO the_DT infected_JJ state_NN of_IN the_DT cell_NN ._SENT In_IN MV_NP infections_NNS ,_, clearance_NN by_IN T_NN lymphocytes_NNS occurs_VBZ during_IN the_DT rash_JJ phase_NN of_IN infection_NN ,_, i.e._FW ,_, 4_CD to_TO 10_CD days_NNS after_IN the_DT onset_NN of_IN disease_NN ._SENT Viral-antigen_NN presentation_NN by_IN class_NN II_CD proteins_NNS is_VBZ critical_JJ to_TO the_DT activation_NN of_IN CD4+_NP T_NN cells_NNS ,_, which_WDT mediate_VBP events_NNS such_JJ as_IN B-cell_NN help_NN in_IN antibody_NN production_NN and_CC cytokine_NN release_NN ._SENT Antigenic_JJ proteins_NNS processed_VBN by_IN antigen-presenting_JJ cells_NNS (_( APCs_NP )_) (_( i.e._FW ,_, monocytes/macrophages_NNS ,_, B_NP cells_NNS ,_, and_CC dendritic_JJ cells_NNS )_) are_VBP deposited_VBN in_IN late_JJ endocytic_JJ compartments_NNS ,_, subjected_VBN to_TO proteolytic_JJ cleavage_NN ,_, and_CC presented_VBN by_IN MHC_NP class_NN II_NP proteins_VBZ to_TO CD4+_NP T_NN cells_NNS ._SENT During_IN MV_NP infections_NNS ,_, class_NN II_NP protein-dependent_NN ,_, CD4+-T-cell-mediated_JJ events_NNS ,_, such_JJ as_IN delayed-type_NN hypersensitivity_NN skin_NN test_NN responses_NNS to_TO recall_VB antigens_NNS ,_, are_VBP suppressed_VBN prior_RB to_TO and_CC long_RB after_IN the_DT MV-induced_JJ rash_NN ._SENT Some_DT antiviral_JJ cytokines_NNS (_( e.g._FW ,_, IFN-alpha/beta_NP and_CC IFN-gamma_NP )_) can_MD activate_VB monocytes/macrophages_NNS to_TO up-regulate_VB MHC_NP class_VB I_PP protein_NN expression_NN and_CC enhance_VB processing_NN of_IN viral_JJ peptides_NNS so_RB that_IN they_PP can_MD be_VB efficiently_RB displayed_VBN by_IN MHC_NP proteins_NNS at_IN the_DT surfaces_NNS of_IN infected_JJ cells_NNS ._SENT Transport_NN of_IN class_NN II_CD proteins_NNS is_VBZ under_IN tight_JJ control_NN since_IN their_PP$ constitutive_JJ expression_NN is_VBZ limited_VBN to_TO classical_JJ APCs_NNS and_CC regulated_VBN by_IN IFN-gamma_NP ._SENT IFN-alpha/beta_NP and_CC IFN-gamma_NP also_RB serve_VBP to_TO inhibit_VB viral_JJ growth_NN and_CC limit_VB the_DT spread_NN of_IN infection_NN ._SENT Although_IN IFN-alpha/beta_NP is_VBZ synthesized_VBN by_IN most_RBS infected_JJ cell_NN types_NNS ,_, synthesis_NN of_IN IFN-gamma_NP is_VBZ restricted_VBN to_TO NK_JJ cells_NNS ,_, NK_JJ T_NN cells_NNS ,_, and_CC T_NN cells_NNS ._SENT IFN-gamma_NP is_VBZ reportedly_RB induced_VBN following_VBG MV_NP infection_NN ._SENT An_DT examination_NN of_IN IFN-gamma_NP levels_NNS in_IN the_DT plasma_NN of_IN measles_NN patients_NNS found_VBD elevated_JJ levels_NNS of_IN the_DT cytokine_NN ,_, primarily_RB during_IN the_DT rash_JJ phase_NN of_IN the_DT illness_NN ._SENT Recent_JJ studies_NNS of_IN MV-infected_JJ Zambian_JJ children_NNS revealed_VBD that_IN IFN-gamma_NP production_NN was_VBD primarily_RB by_IN CD8+_NP T_NN cells_NNS and_CC NK_JJ cells_NNS up_RB to_TO 7_CD days_NNS following_VBG the_DT rash_NN ._SENT In_IN this_DT study_NN ,_, we_PP examine_VBP how_WRB MV_NP affects_VBZ IFN-induced_JJ expression_NN of_IN surface_NN MHC_NP proteins_NNS in_IN human_JJ monocytes_NNS ._SENT Results_NNS from_IN primary_JJ human_JJ monocyte_NN cultures_NNS and_CC from_IN monocyte_NN cell_NN lines_NNS suggest_VBP that_IN MV_NP suppresses_VBZ IFN-gamma-induced_JJ up-regulation_NN of_IN class_NN II_NP protein_NN expression_NN independently_RB of_IN IFN-alpha/beta_NP ._SENT We_PP suggest_VBP that_IN these_DT observations_NNS have_VBP important_JJ implications_NNS for_IN understanding_VBG host_NN resistance_NN to_TO MV_NP infection_NN ._SENT Cell_NN culture_NN ._SENT |_SYM Blood_NP from_IN healthy_JJ adult_NN donors_NNS was_VBD collected_VBN into_IN heparinized_JJ tubes_NNS ,_, and_CC PBMC_NP were_VBD isolated_VBN from_IN lymphocyte_NN separation_NN medium_NN (_( ICN/Cappel_NP ,_, Aurora_NP ,_, Ohio)-generated_JJ buffy_JJ coats_NNS ._SENT Cells_NNS were_VBD collected_VBN and_CC processed_VBN as_IN described_VBN previously_RB ._SENT Monocytes_NNS were_VBD isolated_VBN using_VBG CD14_NP microbeads_NNS (_( Mitenyi_NP Biotec_NP ,_, Auburn_NP ,_, Calif._NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN ._SENT Purity_NN was_VBD assessed_VBN by_IN flow_NN cytometry_NN (_( CD14_NP ,_, CD11b_NP ,_, and_CC CD3_NP )_) and_CC was_VBD >99_JJ %_NN ._SENT Viability_NN as_IN determined_VBN by_IN trypan_JJ blue_JJ exclusion_NN was_VBD >95_JJ %_NN ._SENT In_IN all_DT experiments_NNS ,_, cells_NNS were_VBD cultured_VBN in_IN the_DT presence_NN of_IN heat-inactivated_JJ human_JJ AB_NP serum_NN lacking_VBG MV_NP antibodies_NNS ._SENT Duplicate_JJ experiments_NNS with_IN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) were_VBD done_VBN routinely_RB in_IN parallel_NN ,_, with_IN similar_JJ results_NNS observed_VBD ._SENT Some_DT human_JJ donor_NN cells_NNS were_VBD activated_VBN by_IN FBS_NP and_CC showed_VBD increased_VBN surface_NN MHC_NP expression_NN in_IN the_DT absence_NN of_IN virus_NN ._SENT The_DT limited_JJ numbers_NNS of_IN donor_NN cells_NNS prevented_VBD use_NN of_IN the_DT same_JJ donors_NNS in_IN every_DT experiment_NN ._SENT THP-1_JJ cells_NNS (_( a_DT monocytic_JJ cell_NN line_NN )_) were_VBD maintained_VBN in_IN RPMI_NP medium_NN supplemented_VBD with_IN 0.05_CD mM_NP beta-mercaptoethanol_NN and_CC 10_CD %_NN FBS_NP (_( HyClone_NP ,_, Logan_NP ,_, Utah_NP )_) ._SENT MelJuSo_NP cells_NNS (_( a_DT human_JJ melanoma_NN cell_NN line_NN )_) were_VBD maintained_VBN in_IN RPMI_NP medium_NN supplemented_VBD with_IN 10_CD %_NN FBS_NP ._SENT Virus_NN preparation_NN ._SENT |_SYM All_DT experiments_NNS were_VBD done_VBN with_IN the_DT MV_NP Edmonston_NP (_( Edm_NP )_) strain_NN propagated_VBN in_IN Vero_NP cells_NNS (_( American_NP Type_NP Culture_NP Collection_NP ,_, Manassas_NP ,_, Va._NP )_) ._SENT Preparation_NN of_IN viral_JJ stocks_NNS has_VBZ been_VBN described_VBN previously_RB ._SENT To_TO UV_NP inactivate_VB the_DT virus_NN ,_, 1_CD ml_NN of_IN virus_NN was_VBD placed_VBN in_IN a_DT 35-mm2_JJ petri_NNS dish_NN on_IN ice_NN and_CC exposed_VBD to_TO 400_CD muW_NNS of_IN shortwave_NN UV_NP light/cm2_NN for_IN 8_CD h._JJ UV_NP inactivation_NN of_IN the_DT virus_NN was_VBD confirmed_VBN by_IN a_DT plaque_NN assay_NN of_IN the_DT killed_VBN virus_NN on_IN a_DT Vero_NP monolayer_NN ._SENT In_IN vitro_NN assays_NNS ._SENT |_SYM PBMC_NP (_( 107_CD )_) or_CC purified_VBN monocytes_NNS (_( PM_NP )_) (_( 106_LS )_) were_VBD plated_VBN in_IN 24-well_JJ plates_NNS (_( Corning_NP Incorporated_NP ,_, Corning_NP ,_, N.Y._NP )_) and_CC infected_VBN with_IN MV_NP at_IN a_DT multiplicity_NN of_IN infection_NN (_( MOI_NP )_) of_IN 1_CD for_IN 1_CD h_NN at_IN 37C_JJ in_IN the_DT absence_NN of_IN serum_NN ._SENT Serum_NP subsequently_RB was_VBD added_VBN to_TO a_DT final_JJ concentration_NN of_IN 5_CD %_NN ,_, and_CC the_DT cells_NNS were_VBD maintained_VBN at_IN 37C_JJ for_IN various_JJ incubation_NN times_NNS prior_RB to_TO analysis_NN ._SENT Control_NN cells_NNS were_VBD mock_NN infected_VBN with_IN uninfected_JJ Vero_NP cell_NN lysate_NN ._SENT For_IN some_DT experiments_NNS ,_, purified_VBD monocytes_NNS were_VBD infected_VBN with_IN MV_NP to_TO create_VB APCs_NP ._SENT After_IN 48_CD h_NN ,_, the_DT medium_NN was_VBD removed_VBN from_IN the_DT cells_NNS and_CC replaced_VBN with_IN CD14-depleted_NP PBMC_NP (_( peripheral_JJ blood_NN leukocyte_NN )_) supernatant_JJ previously_RB cultured_VBN for_IN 48_CD h._NN This_DT supernatant_JJ was_VBD prepared_VBN by_IN depleting_VBG PBMC_NP of_IN CD14+_NP monocytes_NNS ._SENT CD14-depleted_NP PBMC_NP were_VBD kept_VBN in_IN culture_NN and_CC then_RB transferred_VBN to_TO the_DT infected_JJ monocytes_NNS after_IN 48_CD h._NN The_DT APCs_NP subsequently_RB were_VBD examined_VBN for_IN surface_NN MHC_NP proteins_NNS by_IN flow_NN cytometric_JJ analysis_NN ._SENT Cells_NNS were_VBD routinely_RB stained_VBN for_IN cytosolic_JJ MV_NP nucleoprotein_NN (_( NP_NP )_) as_IN an_DT indicator_NN of_IN infection_NN ._SENT Cytokine_NN assays_NNS ._SENT |_SYM PM_NP (_( 106_CD )_) were_VBD treated_VBN with_IN 1,000_CD U_NN of_IN IFN-gamma_NP (_( Biosource_NP ,_, Camarillo_NP ,_, Calif._NP ;_: R_NP &_CC D_NP Systems_NPS ,_, Minneapolis_NP ,_, Minn._NP )_) per_IN ml_NN or_CC 200_CD U_NN each_DT of_IN IFN-alpha_NP and_CC IFN-beta_NP (_( Biosource_NP )_) per_IN ml_NN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT In_IN antibody_NN neutralization_NN experiments_NNS ,_, >1,000_JJ U_NN of_IN antibody_NN per_IN ml_NN of_IN PM_NP was_VBD used_VBN ._SENT Anti-IFN-alpha_NN and_CC -IFN-beta_NN antibodies_NNS were_VBD purchased_VBN from_IN Chemicon_NP International_NP (_( Temecula_NP ,_, Calif._NP )_) ._SENT A_DT direct_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) was_VBD used_VBN to_TO quantitate_VB the_DT levels_NNS of_IN IFN-gamma_NP or_CC IFN-alpha_NP in_IN experimental_JJ samples_NNS ._SENT Human_NP IFN-gamma_NP (_( HuIFN-gamma_NP )_) (_( Biosource_NP )_) or_CC HuIFN-alpha_NP (_( R_NP &_CC D_NP Systems_NPS )_) was_VBD used_VBN as_IN the_DT assay_NN standard_NN ._SENT Cytokine_NN controls_NNS and_CC experiment_NN samples_NNS were_VBD added_VBN to_TO anti-IFN_NP antibody-coated_JJ microtiter_NN wells_NNS (_( Biosource_NP or_CC R_NP &_CC D_NP Systems_NPS )_) and_CC assayed_VBD according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN ._SENT In_IN brief_JJ ,_, biotin-labeled_JJ anti-IFN_NN antibody_NN was_VBD used_VBN for_IN detection_NN and_CC streptavidin-horseradish_JJ peroxidase_NN was_VBD used_VBN for_IN enumeration_NN of_IN wells_NNS with_IN an_DT ELISA_NP plate_NN reader_NN at_IN a_DT wavelength_NN of_IN 450_CD nm_NN ._SENT All_DT standards_NNS and_CC unknowns_NNS were_VBD run_VBN in_IN duplicate_NN for_IN each_DT experiment_NN ._SENT Flow_NN cytometry_NN ._SENT |_SYM In_IN brief_NN ,_, cells_NNS were_VBD washed_VBN in_IN phosphate-buffered_JJ saline_NN containing_VBG 0.5_CD %_NN bovine_JJ serum_NN albumin_NN and_CC 0.05_CD %_NN sodium_NN azide_NN (_( FACS_NP buffer_NN )_) and_CC resuspended_JJ in_IN FACS_NP buffer_NN containing_VBG appropriately_RB diluted_JJ antibody_NN ._SENT Cells_NNS were_VBD stained_VBN for_IN surface_NN MHC_NP class_NN I_PP and_CC II_NP protein_NN expression_NN with_IN anti-HLA-A_NP ,_, -B_NN ,_, and_CC -C_NN locus_NN products_NNS (_( clone_NN G46-2.6_NP ;_: BD_NP Bioscience_NP Pharmingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ,_, anti-HLA-DR_NP (_( clone_NN Tu36_NP ;_: BD_NP Bioscience_NP Pharmingen_NP )_) ,_, anti-CD14_NP (_( clone_NN RMO52_NP ;_: Beckman_NP Coulter_NP ,_, Fullerton_NP ,_, Calif._NP )_) ,_, anti-CD3_NP (_( clone_NN UCHT1_NP ;_: Beckman_NP Coulter_NP )_) ,_, fluorescein_NN isothiocyanate-labeled_VBN KK2_NP (_( anti-MV_NP NP_NP ;_: Chemicon_NP International_NP )_) ,_, and_CC CD11b_NP (_( clone_NN Bear_NP 1_CD ;_: Beckman_NP Coulter_NP )_) ._SENT After_IN being_VBG stained_VBN for_IN 20_CD min_NN at_IN 4C_NP ,_, the_DT cells_NNS were_VBD washed_VBN in_IN FACS_NP buffer_NN and_CC then_RB fixed_VBN with_IN 4_CD %_NN paraformaldehyde_NN for_IN 20_CD min_NN at_IN 4C_JJ ._SENT Cells_NNS were_VBD permeabilized_VBN in_IN FACS_NP buffer_NN containing_VBG 0.1_CD %_NN saponin_NN (_( permeabilization_JJ buffer_NN [_SYM PB_NP ]_SYM )_) for_IN 10_CD min_NN at_IN room_NN temperature_NN ._SENT Cells_NNS were_VBD washed_VBN once_RB in_IN PB_NP and_CC then_RB resuspended_JJ in_IN PB_NP containing_VBG a_DT specific_JJ antibody_NN at_IN the_DT appropriate_JJ dilution_NN ._SENT Internal_JJ staining_VBG for_IN MV_NP NP_NP was_VBD carried_VBN out_RP for_IN 30_CD min_NN at_IN room_NN temperature_NN ._SENT Stained_VBN cells_NNS were_VBD analyzed_VBN by_IN use_NN of_IN four-color_JJ flow_NN cytometry_NN (_( Beckman_NP Coulter_NP EPICS-XL_NP )_) and_CC EXPO32_NP ADC_NP software_NN (_( Beckman_NP Coulter_NP )_) ._SENT Side-scatter_NN versus_CC forward-scatter_NN parameters_NNS were_VBD used_VBN to_TO gate_VB cells_NNS by_IN size_NN ._SENT Side-scatter_NN versus_CC cell_NN marker_NN plots_NNS were_VBD used_VBN to_TO analyze_VB each_DT specific_JJ mononuclear_JJ cell_NN population_NN ._SENT Quadrant_NP analysis_NN using_VBG FL1_NP (_( fluorescein_NN isothiocyanate_NN )_) versus_CC FL2_NP (_( phycoerythrin_NN )_) was_VBD used_VBN to_TO differentiate_VB infected_JJ cells_NNS from_IN uninfected_JJ cells_NNS ._SENT Mean_JJ fluorescence_NN intensity_NN measurements_NNS from_IN the_DT generated_VBN plots_NNS are_VBP displayed_VBN as_IN graphs_NNS in_IN the_DT figures_NNS ._SENT Slight_JJ variations_NNS in_IN antibody_NN staining_VBG from_IN experiment_NN to_TO experiment_NN were_VBD common_JJ ,_, but_CC trends_NNS for_IN any_DT given_VBN donor_NN were_VBD always_RB consistent_JJ ._SENT MV_NP Edm_NP infection_NN of_IN human_JJ PBMC_NP does_VBZ not_RB significantly_RB alter_VB MHC_NP class_NN II_NP protein_NN expression_NN ._SENT |_SYM MHC_NP class_NN II_NP protein_NN expression_NN on_IN the_DT surfaces_NNS of_IN PBMC_NP from_IN 10_CD donors_NNS with_IN no_DT documented_VBN recent_JJ exposure_NN to_TO MV_NP or_CC MV_NP vaccine_NN was_VBD examined_VBN following_VBG infection_NN with_IN Edm_NP or_CC mock_JJ infection_NN with_IN Vero_NP cell_NN lysate_NN ._SENT MV_NP infection_NN ,_, confirmed_VBN by_IN testing_NN for_IN MV_NP NP_NP expression_NN in_IN the_DT PBMC_NP specimens_NNS ,_, showed_VBD levels_NNS of_IN NP_NP expression_NN among_IN the_DT PBMC_NP populations_NNS examined_VBD ranging_VBG from_IN 2_CD to_TO 8_CD %_NN ._SENT Detection_NN of_IN cytosolic_JJ NP_NP was_VBD used_VBN to_TO demonstrate_VB successful_JJ infection_NN with_IN MV_NP ._SENT Levels_NNS of_IN cytosolic_JJ NP_NP do_VBP not_RB correlate_VB with_IN the_DT quantity_NN of_IN MV-derived_JJ peptides_NNS that_WDT would_MD be_VB available_JJ for_IN loading_NN onto_IN MHC_NP complexes_NNS ._SENT The_DT range_NN of_IN CD14+_NP expression_NN of_IN the_DT PBMC_NP specimens_NNS examined_VBD before_IN and_CC after_IN infection_NN at_IN an_DT MOI_NP of_IN 1_CD was_VBD 13_CD to_TO 18_CD %_NN ._SENT As_IN a_DT surrogate_NN for_IN evaluating_VBG the_DT antigen-presenting_JJ capability_NN in_IN MV-infected_JJ cells_NNS ,_, cell_NN surface_NN expression_NN of_IN peptide-loaded_JJ MHC_NP proteins_NNS on_IN CD14+_NP PBMC_NP was_VBD evaluated_VBN by_IN use_NN of_IN monoclonal_NN antibody_NN Tu36_NP ,_, which_WDT binds_VBZ to_TO peptide-loaded_JJ class_NN II_NP alpha/beta_NP complexes_NNS at_IN the_DT cell_NN surface_NN ._SENT Class_NP I_NP A_NP ,_, B_NP ,_, and_CC C_NP complexes_NNS were_VBD measured_VBN with_IN antibody_NN G46-2.6_NP at_IN the_DT cell_NN surface_NN ._SENT In_IN the_DT presence_NN or_CC absence_NN of_IN virus_NN ,_, similar90_JJ %_NN of_IN cells_NNS scored_VBD positive_JJ for_IN MHC_NP class_NN I_PP and_CC similar20_JJ %_NN scored_VBD positive_JJ for_IN MHC_NP class_NN II_NP proteins_VBZ ._SENT At_IN MOIs_NN higher_JJR than_IN 1_CD ,_, there_EX was_VBD considerable_JJ loss_NN of_IN the_DT CD14_NP protein_NN on_IN cell_NN surfaces_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT No_DT statistically_RB significant_JJ differences_NNS in_IN the_DT levels_NNS of_IN MHC_NP class_NN II_NP protein_NN expression_NN were_VBD observed_VBN between_IN infected_JJ and_CC uninfected_JJ monocytes_NNS ,_, suggesting_VBG that_IN MV_NP infection_NN does_VBZ not_RB measurably_RB alter_VB the_DT expression_NN of_IN MHC_NP class_NN II_CD complexes_NNS on_IN CD14+_NP MV-infected_NP monocytes_NNS within_IN the_DT PBMC_NP population_NN studied_VBD ._SENT A_DT small_JJ and_CC consistent_JJ increase_NN in_IN class_NN II_NP protein_NN expression_NN was_VBD observed_VBN in_IN 50_CD %_NN of_IN donors_NNS ._SENT However_RB ,_, this_DT increase_NN was_VBD not_RB statistically_RB significant_JJ when_WRB it_PP was_VBD analyzed_VBN by_IN a_DT Student_NP t_NN test_NN ._SENT In_IN contrast_NN ,_, infection_NN of_IN PBMC_NP with_IN Edm_NP resulted_VBD in_IN a_DT two-_NN to_TO threefold_RB increase_VB of_IN peptide-loaded_JJ MHC_NP class_NN I_PP complexes_NNS at_IN the_DT cell_NN surfaces_VBZ of_IN more_JJR than_IN half_NN of_IN the_DT CD14+_NP PBMC_NP specimens_NNS examined_VBD ._SENT These_DT results_NNS showed_VBD that_IN MV_NP infection_NN of_IN PBMC_NP does_VBZ not_RB significantly_RB increase_VB MHC_NP class_NN II_NP protein_NN surface_NN expression_NN but_CC appears_VBZ to_TO augment_VB increased_VBN peptide-loaded_JJ MHC_NP class_NN I_NP expression_NN ._SENT Significant_JJ increased_VBD class_NN II_NP protein_NN surface_NN expression_NN does_VBZ not_RB occur_VB despite_IN the_DT elevated_JJ levels_NNS of_IN IFN-gamma_NP expression_NN that_IN result_NN from_IN infection_NN ._SENT To_TO further_RBR evaluate_VB this_DT effect_NN ,_, we_PP examined_VBD MHC_NP expression_NN on_IN PM_NP from_IN two_CD donors_NNS ,_, C_NP and_CC F_NP ,_, following_VBG Edm_NP or_CC mock_JJ infection_NN ._SENT As_IN predicted_VBN from_IN the_DT PBMC_NP studies_NNS ,_, no_DT significant_JJ increase_NN of_IN surface_NN MHC_NP class_NN II-peptide-loaded_JJ complexes_NNS was_VBD detected_VBN 24_CD to_TO 48_CD h_NN after_IN infection_NN ._SENT Kinetic_JJ studies_NNS have_VBP shown_VBN that_IN increased_VBN class_NN I_PP surface_VBP expression_NN mediated_VBN by_IN IFN-gamma_NP in_IN cell_NN lines_NNS precedes_VBZ the_DT induction_NN of_IN class_NN II_NP protein_NN expression_NN and_CC peaks_NNS earlier_RBR ;_: therefore_RB ,_, we_PP also_RB examined_VBD cells_NNS at_IN 72_CD h_NN after_IN infection_NN ._SENT At_IN the_DT later_JJR time_NN point_NN ,_, surface_NN class_NN II_NP protein_NN levels_NNS began_VBD to_TO decrease_VB ,_, not_RB increase_VB (_( data_NNS not_RB shown_VBN )_) ._SENT As_RB in_IN PBMC_NP ,_, an_DT approximately_RB twofold_JJ elevation_NN in_IN MHC_NP class_NN I_NP HLA-A_NP ,_, -B_NN ,_, and_CC -C_NN proteins_NNS was_VBD detected_VBN in_IN the_DT PM_NP at_IN 48_CD h_NN after_IN infection_NN ._SENT UV-inactivated_NP MV_NP also_RB elevated_VBD class_NN I_PP proteins_VBZ in_IN this_DT assay_NN (_( data_NNS not_RB shown_VBN )_) ._SENT MHC_NP class_NN II_NP protein_NN expression_NN on_IN MV-infected_NP CD14+_NP cells_NNS is_VBZ not_RB significantly_RB affected_VBN by_IN increasing_VBG MOI_NP ._SENT |_SYM MHC_NP class_NN II_NP protein_NN expression_NN on_IN PM_NP or_CC PBMC_NP was_VBD examined_VBN following_VBG infection_NN with_IN 0_CD ,_, 0.1_CD ,_, 1_CD ,_, 5_CD ,_, and_CC 10_CD MOIs_NP of_IN Edm_NP ._SENT With_IN increasing_VBG amounts_NNS of_IN inoculating_VBG virus_NN ,_, no_DT significant_JJ differences_NNS in_IN peptide-loaded_JJ MHC_NP class_NN II_NP protein_NN expression_NN were_VBD observed_VBN for_IN Edm-infected_NP PM_NP or_CC PBMC_NP at_IN 48_CD h_NN after_IN infection_NN ._SENT In_IN addition_NN ,_, similar_JJ levels_NNS of_IN MHC_NP class_NN II_NP protein_NN expression_NN were_VBD detected_VBN when_WRB anti-DP_JJ and_CC -DQ_JJ class_NN II_NP antibodies_NNS were_VBD used_VBN ,_, suggesting_VBG that_IN levels_NNS of_IN class_NN II_NP DP_NP and_CC DQ_NP proteins_NNS ,_, like_IN levels_NNS of_IN DR_NP proteins_NNS ,_, were_VBD not_RB affected_VBN by_IN Edm_NP infection_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Furthermore_RB ,_, identical_JJ profiles_NNS were_VBD seen_VBN in_IN tests_NNS for_IN surface_NN class_NN II_NP DR_NP proteins_NNS with_IN the_DT DR-specific_NP antibody_NN L243_NP ,_, indicating_VBG that_IN class_NN II_NP molecules_NNS in_IN MV-infected_JJ monocytes_NNS had_VBD not_RB lost_VBN the_DT Tu36_NP epitope_NN (_( data_NNS not_RB shown_VBN )_) ._SENT To_TO confirm_VB that_DT MHC_NP class_NN II_NP protein_NN expression_NN could_MD be_VB elevated_VBN on_IN PM_NP and_CC PBMC_NP ,_, mock-infected_JJ and_CC Edm-infected_JJ cells_NNS were_VBD treated_VBN with_IN 1,000_CD U_NN of_IN recombinant_JJ HuIFN-gamma_NP per_IN ml_NN of_IN sample_NN ._SENT The_DT units_NNS of_IN cytokines_NNS used_VBN to_TO treat_VB the_DT cells_NNS were_VBD determined_VBN on_IN the_DT basis_NN of_IN published_VBN literature_NN and_CC on_IN dose-response_NN experiments_NNS on_IN PM_NP (_( data_NN not_RB shown_VBN )_) ._SENT Interestingly_RB ,_, although_IN levels_NNS of_IN MHC_NP class_NN II_NP proteins_NNS were_VBD increased_VBN on_IN IFN-gamma-treated_NP PBMC_NP ,_, MV_NP appeared_VBD to_TO suppress_VB IFN-gamma-mediated_JJ up-regulation_NN of_IN surface_NN MHC_NP class_NN II_NP protein_NN expression_NN on_IN PM_NP cells_NNS ,_, and_CC it_PP did_VBD so_RB even_RB after_IN 72_CD h_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Similar_JJ levels_NNS of_IN MV_NP NP_NP were_VBD detected_VBN for_IN treated_VBN and_CC untreated_JJ PBMC_NP and_CC PM_NP (_( data_NN not_RB shown_VBN )_) ,_, though_IN IFN-gamma_NP has_VBZ been_VBN shown_VBN to_TO inhibit_VB MV_NP replication_NN ._SENT Taken_VBN together_RB ,_, these_DT results_NNS further_RBR suggest_VB that_DT MV_NP infection_NN results_NNS in_IN a_DT failure_NN to_TO up-regulate_JJ class_NN II_NP protein_NN expression_NN ._SENT It_PP is_VBZ also_RB possible_JJ that_IN MV_NP infection_NN results_NNS in_IN the_DT elevation_NN of_IN additional_JJ factors_NNS in_IN PM_NP that_IN further_RBR interfere_VB with_IN class_NN II_NP protein_NN surface_NN expression_NN ._SENT MV_NP infection_NN is_VBZ associated_VBN with_IN IFN-alpha_NP production_NN ._SENT |_SYM MV_NP induces_VBZ infected_JJ human_JJ monocytes_NNS to_TO produce_VB IFN-alpha_NP ,_, and_CC in_IN turn_NN ,_, IFN-alpha_NP suppresses_VBZ MV_NP replication_NN in_IN those_DT cells_NNS ._SENT To_TO determine_VB the_DT levels_NNS of_IN IFN_NP expression_NN associated_VBN with_IN Edm_NP infection_NN of_IN PBMC_NP or_CC PM_NP ,_, supernatants_NNS from_IN Edm-infected_NP PBMC_NP and_CC PM_NP were_VBD examined_VBN for_IN IFN-alpha_NP and_CC IFN-gamma_NP expression_NN ._SENT Equivalent_JJ numbers_NNS of_IN CD14+_NP cells_NNS were_VBD examined_VBN in_IN the_DT PM_NP and_CC PBMC_NP ._SENT Measurements_NNS of_IN IFN-alpha_NP and_CC IFN-gamma_NP levels_NNS in_IN the_DT supernatants_NNS of_IN Edm-infected_NP PBMC_NP or_CC PM_NP showed_VBD considerable_JJ induction_NN of_IN IFN-alpha_NP (_( similar100_NP U/ml_NP )_) in_IN all_DT virus-infected_JJ supernatants_NNS and_CC induction_NN of_IN IFN-gamma_NP (_( similar17_JJ to_TO 20_CD U/ml_NN )_) in_IN MV-infected_NP PBMC_NP ._SENT These_DT findings_NNS are_VBP consistent_JJ with_IN reports_NNS of_IN IFN-alpha_NP being_VBG produced_VBN primarily_RB by_IN monocytes_NNS and_CC consistent_JJ with_IN the_DT localization_NN of_IN MV_NP NP_NP to_TO CD14+_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT As_IN a_DT control_NN ,_, the_DT levels_NNS of_IN IFN-alpha_NP expression_NN by_IN Edm-infected_JJ and_CC uninfected_JJ Vero_NP cells_NNS were_VBD determined_VBN ,_, and_CC as_RB expected_VBN ,_, no_DT substantial_JJ levels_NNS of_IN expression_NN were_VBD observed_VBN ._SENT It_PP thus_RB appears_VBZ that_DT inhibition_NN of_IN increased_VBN MHC_NP class_NN II_NP protein_NN expression_NN on_IN PM_NP occurs_VBZ in_IN the_DT presence_NN of_IN IFN-alpha_NP ._SENT Up-regulation_NN of_IN MHC_NP proteins_NNS by_IN IFN-gamma_NP is_VBZ suppressed_VBN in_IN MV-infected_NP CD14+_NP cells_NNS ._SENT |_SYM MHC_NP expression_NN on_IN PM_NP or_CC PBMC_NP was_VBD examined_VBN following_VBG infection_NN of_IN cells_NNS with_IN live_JJ virus_NN or_CC treatment_NN with_IN UV-inactivated_JJ virus_NN ._SENT IFN-gamma-induced_JJ expression_NN of_IN both_DT class_NN I_PP and_CC class_VB II_NP proteins_NNS in_IN Edm-containing_NP PM_NP was_VBD inhibited_VBN compared_VBN with_IN expression_NN in_IN the_DT control_NN ._SENT Thus_RB ,_, only_RB the_DT IFN-gamma-treated_JJ control_NN PM_NP up-regulated_JJ class_NN I_PP and_CC class_VB II_NP surface_NN complexes_NNS ._SENT In_IN contrast_NN ,_, IFN-gamma-treated_NP PBMC_NP elevated_VBD class_NN I_PP and_CC class_VB II_NP protein_NN expression_NN in_IN both_DT control_NN and_CC Edm-infected_JJ cells_NNS ,_, further_RBR suggesting_VBG that_IN the_DT PM_NP may_MD lack_VB factors_NNS necessary_JJ to_TO activate_VB increased_VBN class_NN II_NP protein_NN expression_NN ._SENT PM_NP are_VBP depleted_VBN of_IN numerous_JJ cytokine-producing_NN cells_NNS ._SENT Suppression_NN of_IN class_NN II_NP protein_NN expression_NN was_VBD also_RB detected_VBN following_VBG treatment_NN of_IN PM_NP with_IN killed_VBN MV_NP ._SENT Treatment_NN with_IN UV-inactivated_JJ virus_NN did_VBD not_RB up-regulate_JJ class_NN II_NP protein_NN surface_NN expression_NN ,_, and_CC the_DT inactivated_VBN virus_NN may_MD suppress_VB IFN-gamma-induced_JJ up-regulation_NN of_IN class_NN II_NP protein_NN expression_NN ._SENT These_DT same_JJ observations_NNS were_VBD made_VBN when_WRB supernatants_NNS from_IN Edm-infected_JJ monocytes_NNS were_VBD inactivated_VBN and_CC then_RB added_VBD to_TO a_DT fresh_JJ culture_NN of_IN monocytes_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS suggested_VBD that_IN viral_JJ replication_NN was_VBD not_RB required_VBN to_TO inhibit_VB IFN-gamma-induced_JJ up-regulation_NN of_IN MHC_NP proteins_NNS in_IN PM_NP ._SENT Since_IN IFN-alpha_NP was_VBD detected_VBN in_IN the_DT monocyte-derived_JJ supernatant_JJ ,_, we_PP tested_VBD whether_IN neutralizing_VBG IFN-alpha/beta_NP would_MD allow_VB IFN-gamma_NP to_TO up-regulate_VB class_NN II_NP protein_NN expression_NN ._SENT However_RB ,_, antibody_NN neutralization_NN of_IN IFN-alpha/beta_NP also_RB failed_VBD to_TO prevent_VB the_DT inhibition_NN of_IN IFN-gamma-induced_JJ up-regulation_NN of_IN class_NN II_NP protein_NN expression_NN ,_, thus_RB implying_VBG that_IN IFN-alpha/beta_NP did_VBD not_RB directly_RB inhibit_VB IFN-gamma_NP ._SENT Taken_VBN together_RB ,_, the_DT data_NNS suggest_VBP that_IN IFN-alpha/beta_NP may_MD not_RB play_VB a_DT role_NN in_IN the_DT inhibition_NN of_IN IFN-gamma-induced_JJ up-regulation_NN of_IN surface_NN class_NN II_NP peptide-loaded_JJ complexes_NNS on_IN peripheral_JJ monocytes_NNS ._SENT IFN-alpha/beta_NP does_VBZ not_RB prevent_VB IFN-gamma-induced_JJ elevation_NN of_IN class_NN II_CD proteins_NNS in_IN PM_NP ._SENT |_SYM Class_NN I_PP and_CC class_VB II_NP proteins_NNS were_VBD analyzed_VBN on_IN PM_NP 48_CD h_NN following_VBG treatment_NN with_IN IFNs_NP ._SENT As_IN expected_VBN ,_, IFN-gamma_NP treatment_NN elevated_VBD both_DT class_NN I_PP and_CC class_VB II_NP proteins_NNS ,_, whereas_IN IFN-alpha/beta_NP treatment_NN elevated_VBD only_RB class_VB I_PP protein_NN expression_NN ._SENT Contrary_JJ to_TO findings_NNS for_IN cell_NN lines_NNS ,_, IFN-alpha/beta_NP treatment_NN did_VBD not_RB inhibit_VB IFN-gamma-induced_JJ expression_NN of_IN surface_NN class_NN II_CD proteins_NNS in_IN any_DT donor_NN tested_VBD ._SENT The_DT effects_NNS of_IN type_NN I_PP IFNs_NNS on_IN IFN-gamma-induced_JJ class_NN II_NP protein_NN expression_NN have_VBP previously_RB been_VBN reported_VBN to_TO be_VB tissue_NN specific_JJ and_CC not_RB to_TO occur_VB in_IN human_JJ PM_NP ._SENT Only_JJ class_NN I_PP proteins_VBZ are_VBP elevated_VBN in_IN MV-infected_JJ class_NN II_NP protein-positive_JJ cell_NN lines_NNS ._SENT |_SYM Class_NP II_NP protein-positive_JJ cell_NN lines_NNS MelJuSo_NP and_CC THP-1_NP were_VBD infected_VBN with_IN Vero_NP cell-adapted_JJ Edm_NN for_IN 48_CD h_NN ,_, and_CC the_DT cell_NN surfaces_NNS were_VBD scored_VBN for_IN class_NN II_NP protein_NN expression_NN ._SENT Levels_NNS of_IN class_NN I_PP proteins_VBZ were_VBD recorded_VBN for_IN comparison_NN ._SENT Both_CC cell_NN lines_NNS were_VBD readily_RB infected_VBN with_IN Edm_NP (_( similar40_JJ %_NN of_IN both_DT cells_NNS lines_NNS scored_VBD positive_JJ for_IN MV_NP NP_NP )_) ._SENT Greater_JJR than_IN 90_CD %_NN of_IN both_DT cell_NN lines_NNS scored_VBD positive_JJ for_IN class_NN I_PP and_CC class_VB II_NP protein_NN expression_NN ;_: only_RB 4_CD %_NN of_IN THP-1_JJ cells_NNS scored_VBD positive_JJ for_IN class_NN II_NP protein_NN expression_NN ._SENT MV_NP infection_NN elevated_VBD class_NN I_PP proteins_VBZ two-_NN to_TO fourfold_JJ ,_, and_CC this_DT augmentation_NN was_VBD dose_NN dependent_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Class_NP II_NP protein_NN expression_NN was_VBD not_RB elevated_VBN at_IN 48_CD h_NN or_CC at_IN 24_CD or_CC 72_CD h_NN (_( data_NNS not_RB shown_VBN )_) after_IN infection_NN ._SENT In_IN addition_NN ,_, no_DT IFN-alpha_NP was_VBD detected_VBN in_IN the_DT supernatant_JJ by_IN ELISA_NP (_( data_NN not_RB shown_VBN )_) ._SENT We_PP therefore_RB conclude_VBP that_IN MV-infected_JJ cell_NN lines_NNS also_RB fail_VBP to_TO up-regulate_VB class_NN II_CD proteins_NNS following_VBG infection_NN ._SENT Under_IN these_DT conditions_NNS ,_, no_DT IFN-alpha_NP was_VBD released_VBN into_IN the_DT supernatant_JJ ,_, suggesting_VBG that_IN at_IN a_DT minimum_NN ,_, IFN-alpha_NP did_VBD not_RB play_VB a_DT role_NN in_IN suppressing_VBG class_NN II_NP protein_NN enhancement_NN following_VBG MV_NP infection_NN ._SENT Thus_RB ,_, the_DT data_NNS do_VBP not_RB support_VB a_DT role_NN for_IN IFN-alpha/beta_NP in_IN suppressing_VBG class_NN II_NP protein_NN levels_NNS in_IN Edm-infected_JJ monocytic_JJ cells_NNS ._SENT PBMC-derived_JJ factors_NNS promote_VBP an_DT increase_NN in_IN surface_NN class_NN II_NP protein_NN expression_NN in_IN Edm-infected_NP CD14+_NP cells_NNS ._SENT |_SYM It_PP might_MD be_VB inferred_VBN from_IN the_DT data_NN that_IN MV-infected_NP PM_NP respond_VB to_TO exogenous_JJ IFN-gamma_NP if_IN they_PP are_VBP sufficiently_RB activated_VBN ._SENT To_TO test_VB this_DT ,_, surface_NN class_NN II_NP protein_NN levels_NNS on_IN Edm-infected_NP PM_NP were_VBD examined_VBN following_VBG treatment_NN with_IN supernatants_NNS derived_VBN from_IN CD14-depleted_NP PBMC_NP ._SENT At_IN 96_CD h_NN ,_, similar16_JJ %_NN of_IN CD14_NP cells_NNS scored_VBD positive_JJ for_IN class_NN II_NP protein_NN without_IN the_DT PBMC-derived_JJ supernatant_JJ ,_, whereas_IN similar78_JJ %_NN of_IN CD14_NP cells_NNS scored_VBD positive_JJ for_IN class_NN II_NP protein_NN with_IN the_DT PBMC-derived_JJ supernatant_JJ ._SENT Similarly_RB ,_, similar17_JJ %_NN of_IN CD14_NP cells_NNS scored_VBD positive_JJ for_IN class_NN I_CD protein_NN without_IN the_DT PBMC_NP supernatant_JJ ,_, whereas_IN for_IN both_DT mock-_NN and_CC Edm-infected_JJ cells_NNS ,_, similar65_JJ %_NN of_IN CD14_NP cells_NNS scored_VBD positive_JJ for_IN class_NN I_CD protein_NN with_IN the_DT PBMC_NP supernatant_JJ ._SENT The_DT supernatant_JJ derived_VBN from_IN peripheral_JJ blood_NN leukocytes_NNS contained_VBD similar20_NP U_NP of_IN IFN-gamma_NP per_IN ml_NN as_IN determined_VBN by_IN ELISA_NP ._SENT Treatment_NN with_IN the_DT PBMC-derived_JJ supernatant_JJ stimulates_VBZ PM_NP and_CC restores_VBZ class_NN II_NP protein_NN levels_NNS to_TO those_DT of_IN the_DT control_NN ._SENT We_PP confirmed_VBD a_DT partial_JJ role_NN for_IN IFN-gamma_NP in_IN this_DT restoration_NN through_IN antibody_NN blocking_VBG experiments_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT It_PP is_VBZ highly_RB likely_JJ that_IN additional_JJ cytokines_NNS ,_, which_WDT contribute_VBP to_TO activation_NN of_IN the_DT monocytes_NNS ,_, also_RB play_VB a_DT role_NN ._SENT These_DT factors_NNS ,_, in_IN concert_NN with_IN IFN-gamma_NP ,_, appear_VBP responsible_JJ for_IN elevating_VBG class_NN II_CD proteins_NNS in_IN stimulated_VBN Edm-infected_JJ monocytes_NNS ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN MV_NP up-regulates_VBZ the_DT surface_NN expression_NN of_IN class_NN II_CD proteins_NNS in_IN human_JJ PM_NP and_CC ,_, furthermore_RB ,_, that_IN IFN-gamma_NP ,_, the_DT activator_NN of_IN class_NN II_NP transcription_NN ,_, is_VBZ not_RB involved_VBN in_IN this_DT process_NN ._SENT The_DT type_NN I_PP IFNs_NNS (_( i.e._FW ,_, IFN-alpha_NP and_CC -beta_NNS )_) are_VBP induced_VBN in_IN MV-infected_JJ monocytes_NNS and_CC appear_VBP to_TO inhibit_VB viral_JJ pathogenesis_NN by_IN halting_VBG viral_JJ replication_NN ._SENT Interestingly_RB ,_, IFN-alpha_NP and_CC -beta_NP have_VBP recently_RB been_VBN shown_VBN to_TO interfere_VB with_IN or_CC suppress_VB class_NN II_NP protein_NN expression_NN in_IN many_JJ viral_JJ systems_NNS ._SENT Thus_RB ,_, it_PP appears_VBZ from_IN the_DT literature_NN that_IN MV_NP infection_NN results_NNS in_IN an_DT up-regulation_NN of_IN MHC_NP class_NN II_CD molecules_NNS in_IN an_DT IFN-alpha/beta-rich_NP milieu_NN ._SENT In_IN an_DT effort_NN to_TO resolve_VB this_DT paradox_NN ,_, the_DT present_JJ study_NN was_VBD done_VBN to_TO examine_VB the_DT influence_NN of_IN type_NN I_PP and_CC type_NN II_NP IFNs_NP on_IN class_NN II_NP protein_NN surface_NN expression_NN in_IN MV-infected_JJ monocytes_NNS ._SENT We_PP were_VBD surprised_VBN to_TO find_VB that_DT MV_NP infection_NN of_IN purified_VBN monocytes_NNS did_VBD not_RB significantly_RB alter_VB the_DT expression_NN of_IN surface-displayed_JJ MHC_NP class_NN II_NP proteins_VBZ ,_, a_DT finding_NN in_IN contrast_NN with_IN that_DT from_IN the_DT earlier_JJR report_NN ._SENT Moreover_RB ,_, MV-infected_NP purified_VBD monocytes_NNS failed_VBD to_TO up-regulate_VB class_NN II_CD proteins_NNS following_VBG stimulation_NN with_IN IFN-gamma_NP ,_, an_DT event_NN that_WDT readily_RB occurs_VBZ in_IN the_DT absence_NN of_IN virus_NN when_WRB cells_NNS are_VBP treated_VBN with_IN exogenous_JJ IFN-gamma_NP ._SENT We_PP found_VBD that_IN IFN-alpha/beta_NP ,_, at_IN least_JJS in_IN the_DT specific_JJ case_NN of_IN MV-infected_JJ human_JJ monocytes_NNS ,_, does_VBZ not_RB appear_VB to_TO play_VB a_DT role_NN in_IN this_DT inhibition_NN ._SENT Finally_RB ,_, we_PP showed_VBD that_IN the_DT addition_NN of_IN MV-infected_NP PBMC_NP culture_NN supernatant_JJ to_TO purified_VBN monocytes_NNS results_NNS in_IN greater_JJR surface_NN expression_NN of_IN class_NN II_CD molecules_NNS than_IN does_VBZ the_DT addition_NN of_IN exogenous_JJ IFN-gamma_NNS alone_RB ,_, suggesting_VBG that_IN additional_JJ factors_NNS play_VBP a_DT role_NN in_IN MHC_NP class_NN II_NP protein_NN regulation_NN in_IN this_DT system_NN ._SENT Expression_NN of_IN MHC_NP class_NN II_CD proteins_NNS on_IN monocytes_NNS is_VBZ central_JJ to_TO the_DT development_NN of_IN CD4-mediated_JJ T-cell_NN responses_NNS ._SENT Activated_VBN APCs_NNS expressing_VBG MHC_NP class_NN II_CD molecules_NNS along_IN with_IN appropriate_JJ costimulatory_JJ molecules_NNS present_VBP processed_JJ antigens_NNS to_TO CD4+_NP T_NN cells_NNS ._SENT CD4+_JJ T_NN cells_NNS in_IN turn_NN regulate_VB both_DT cellular_JJ and_CC humoral_JJ immune_JJ responses_NNS ._SENT Cytokines_NNS produced_VBN by_IN activated_VBN CD4+_NP T_NN cells_NNS ,_, CD8+_NP T_NN cells_NNS ,_, and_CC innate_JJ immune_JJ cells_NNS orchestrate_VBP the_DT developing_VBG immune_JJ response_NN ._SENT Failure_NN to_TO up-regulate_JJ class_NN II_NP protein_NN expression_NN following_VBG MV_NP infection_NN may_MD provide_VB a_DT mechanism_NN to_TO delay_VB the_DT onset_NN of_IN CD4-mediated_JJ T-cell_NN responses_NNS ,_, such_JJ as_IN macrophage_NN activation_NN and_CC IFN-gamma_NP production_NN ,_, thereby_RB facilitating_VBG MV_NP replication_NN and_CC spread_NN ._SENT CD8+_JJ T_NN cells_NNS are_VBP known_VBN to_TO clear_VB MV-infected_JJ cells_NNS in_IN the_DT context_NN of_IN substantial_JJ suppression_NN of_IN CD4+-T-cell-mediated_JJ events_NNS ._SENT In_IN addition_NN ,_, an_DT investigation_NN of_IN cytokine_NN levels_NNS in_IN children_NNS with_IN measles_NN found_VBD that_IN it_PP was_VBD predominantly_RB the_DT CD8+-T-cell_NN and_CC NK_JJ cell_NN lymphocyte_NN population_NN ,_, not_RB the_DT CD4+-T-cell_NN population_NN ,_, that_WDT produced_VBD IFN-gamma_NP ._SENT Findings_NNS from_IN our_PP$ study_NN of_IN MV-infected_JJ monocytes_NNS are_VBP consistent_JJ with_IN those_DT observations_NNS since_IN they_PP demonstrate_VBP a_DT circumstance_NN in_IN which_WDT class_NN I-restricted_JJ activation_NN may_MD occur_VB in_IN the_DT context_NN of_IN reduced_VBN class_NN II_NP protein-restricted_JJ activation_NN ._SENT A_DT number_NN of_IN microorganisms_NNS evade_VBP immune_JJ surveillance_NN by_IN preventing_VBG signaling_VBG via_IN class_NN II_CD proteins_NNS ._SENT For_IN example_NN ,_, Toxoplasma_NP gondii_NP causes_VBZ down-regulation_NN of_IN MHC_NP class_NN II_NP molecules_NNS and_CC an_DT inability_NN to_TO up-regulate_VB class_NN I_PP molecules_NNS ,_, and_CC the_DT Epstein-Barr_NP virus_NN gene_NN BZLF2_NP encodes_VBZ a_DT 42-kDa_JJ protein_NN that_WDT interacts_VBZ with_IN the_DT HLA-DR_NP beta_NN chain_NN and_CC inhibits_VBZ class_NN II_NP protein-dependent_JJ antigen_NN presentation_NN in_IN B_NP cells_NNS ._SENT Furthermore_RB ,_, human_JJ cytomegalovirus_NN encodes_VBZ a_DT protein_NN ,_, US2_NP ,_, that_WDT targets_VBZ class_NN II_NP DR-alpha_NP and_CC DM-alpha_NP molecules_NNS for_IN degradation_NN by_IN the_DT proteosome_NN ._SENT Human_JJ immunodeficiency_NN virus_NN infection_NN has_VBZ also_RB been_VBN shown_VBN to_TO impair_VB class_NN II_NP protein_NN expression_NN in_IN infected_JJ primary_JJ monocytes_NNS ._SENT Two_CD fairly_RB well_RB characterized_VBN mechanisms_NNS that_WDT explain_VBP how_WRB some_DT viruses_NNS interfere_VBP with_IN class_NN II_NP protein_NN signaling_VBG have_VB been_VBN described_VBN ._SENT In_IN these_DT mechanisms_NNS ,_, IFN-alpha/beta_NP and/or_CC viral_JJ gene_NN products_NNS down-regulate_JJ class_NN II_NP gene_NN transcription_NN by_IN down-regulating_VBG levels_NNS of_IN the_DT class_NN II_NP transcriptional_JJ activator_NN (_( CIITA_NP )_) protein_NN ._SENT Paramyxoviruses_NNS are_VBP reported_VBN to_TO interfere_VB with_IN the_DT cytokine_NN signaling_VBG pathways_NNS of_IN the_DT IFNs_NP ._SENT We_PP examined_VBD the_DT influence_NN of_IN type_NN I_PP and_CC type_NN II_NP IFNs_NP on_IN class_NN II_NP protein_NN expression_NN in_IN MV-infected_JJ monocytes_NNS ._SENT Our_PP$ results_NNS show_VBP that_IN MV_NP inhibits_VBZ IFN-gamma-induced_JJ expression_NN of_IN class_NN II_CD proteins_NNS ,_, and_CC they_PP strongly_RB suggest_VBP that_IN this_DT inhibition_NN does_VBZ not_RB occur_VB via_IN IFN-alpha/beta_NP ._SENT IFN-alpha/beta_NP was_VBD of_IN interest_NN because_IN of_IN the_DT known_VBN role_NN of_IN IFN-alpha/beta_NP in_IN suppressing_VBG IFN-gamma-induced_JJ expression_NN of_IN class_NN II_CD proteins_NNS in_IN CIITA-transfected_JJ human_JJ cells_NNS ,_, mouse_NN cytomegalovirus-infected_JJ mouse_NN macrophages_NNS ,_, human_JJ cytomegalovirus-infected_JJ human_JJ endothelial_JJ cells_NNS ,_, and_CC human_JJ parainfluenza_NN virus_NN 3-infected_JJ human_JJ cell_NN lines_NNS ._SENT However_RB ,_, this_DT did_VBD not_RB appear_VB to_TO be_VB the_DT mechanism_NN by_IN which_WDT increased_VBD class_NN II_NP protein_NN surface_NN expression_NN was_VBD prevented_VBN in_IN MV-infected_JJ monocytes_NNS ._SENT The_DT above-mentioned_JJ studies_NNS also_RB report_VBP a_DT role_NN for_IN viral_JJ gene_NN products_NNS in_IN suppressing_VBG class_NN II_NP gene_NN transcription_NN ._SENT On_IN the_DT basis_NN of_IN recent_JJ studies_NNS of_IN Sendai_NP virus_NN ,_, it_PP has_VBZ been_VBN suggested_VBN that_IN MV_NP likely_RB uses_VBZ its_PP$ nonstructural_JJ V_CD and_CC C_NP proteins_NNS to_TO obstruct_VB IFN_NP responses_NNS ._SENT We_PP plan_VBP to_TO examine_VB correlations_NNS between_IN V_CD and_CC C_NP protein_NN expression_NN and_CC MHC_NP expression_NN in_IN MV-infected_JJ monocytes_NNS ._SENT An_DT examination_NN of_IN specific_JJ viral_JJ proteins_NNS which_WDT interfere_VBP with_IN the_DT IFN_NP response_NN is_VBZ the_DT subject_NN of_IN ongoing_JJ work_NN in_IN our_PP$ laboratory_NN ._SENT Wild-type_NN and_CC vaccine_NN strains_NNS of_IN MV_NP appear_VBP to_TO differ_VB both_DT in_IN their_PP$ response_NN to_TO type_VB I_PP and_CC type_NN II_NP IFNs_NP and_CC in_IN their_PP$ ability_NN to_TO induce_VB IFN-alpha/beta_NP in_IN infected_JJ cells_NNS ._SENT Vaccine_NN strains_NNS ,_, or_CC strains_NNS that_WDT have_VBP been_VBN laboratory_NN adapted_VBN in_IN Vero_NP cells_NNS ,_, which_WDT use_VBP CD46_NP for_IN entry_NN ,_, were_VBD shown_VBN to_TO induce_VB significant_JJ levels_NNS of_IN IFN-alpha/beta_NP ,_, whereas_IN wild-type_NN strains_NNS and_CC B95a-passaged_JJ strains_NNS induced_VBD 10-_CD to_TO 80-fold_NN less_CC IFN-alpha/beta_NP ._SENT In_IN our_PP$ model_NN system_NN ,_, vaccine_NN strains_NNS use_VBP CD46_NP for_IN entry_NN ,_, readily_RB infect_VB the_DT monocyte_NN population_NN ,_, and_CC secrete_VB IFN-alpha_NP ._SENT Though_IN wild-type_JJ MV_NP strains_NNS use_VBP the_DT receptor_NN CDw150_NP or_CC the_DT human_JJ signaling_VBG lymphocyte_NN activation_NN molecule_NN for_IN entry_NN ,_, recent_JJ data_NNS suggest_VBP that_IN they_PP also_RB use_VBP CD46_NP for_IN entry_NN ,_, albeit_IN with_IN lower_JJR affinity_NN ._SENT Pilot_NN experiments_NNS carried_VBD out_RP with_IN wild-type_NN strains_NNS of_IN MV_NP in_IN this_DT system_NN revealed_VBD low_JJ levels_NNS of_IN infection_NN and_CC no_DT up-regulation_NN of_IN class_NN II_CD proteins_NNS and_CC did_VBD not_RB detect_VB IFN-alpha_NP in_IN supernatant_JJ fluids_NNS (_( unpublished_JJ observations_NNS )_) ._SENT Since_IN wild-type_NN viruses_NNS reportedly_RB inhibit_VBP the_DT secretion_NN of_IN IFN-alpha/beta_NP ,_, we_PP plan_VBP to_TO examine_VB the_DT impact_NN of_IN wild-type_NN entry_NN via_IN the_DT human_JJ signaling_VBG lymphocyte_NN activation_NN molecule_NN on_IN class_NN II_NP protein_NN surface_NN expression_NN ._SENT It_PP is_VBZ possible_JJ that_IN wild-type_NN viruses_NNS not_RB yet_RB adapted_VBN to_TO Vero_NP cells_NNS up-regulate_VBP class_NN II_CD molecules_NNS ._SENT Jacobson_NP et_FW al._FW reported_VBD that_IN much_RB of_IN the_DT cytotoxic-T-lymphocyte_NN (_( CTL_NP )_) response_NN to_TO measles_NN in_IN humans_NNS was_VBD MHC_NP class_NN II_NP protein_NN restricted_VBD ._SENT Others_NNS have_VBP reported_VBN that_IN although_IN CD4+-_NN and_CC CD8+-T-cell_NN killing_NN of_IN MV-infected_JJ cells_NNS was_VBD intact_JJ in_IN the_DT system_NN examined_VBD ,_, these_DT CTLs_NNS were_VBD slow_JJ to_TO be_VB generated_VBN ._SENT It_PP was_VBD proposed_VBN that_IN this_DT ability_NN to_TO delay_VB the_DT generation_NN of_IN CTLs_NP would_MD eventually_RB allow_VB killing_VBG but_CC only_RB after_IN additional_JJ viral_JJ spread_NN ._SENT We_PP are_VBP keen_JJ to_TO determine_VB whether_IN such_JJ delays_NNS are_VBP promoted_VBN by_IN reduced_VBN class_NN II_NP protein_NN signaling_VBG ._SENT Though_IN MV_NP may_MD not_RB directly_RB target_VB antigen_NN presentation_NN by_IN class_NN II_CD proteins_NNS ,_, its_PP$ probable_JJ effects_NNS on_IN cytokines_NNS that_WDT regulate_VBP class_NN II_NP protein_NN transcription_NN and_CC membrane_NN trafficking_NN may_MD ultimately_RB affect_VB surface_NN deposition_NN of_IN class_NN II_CD complexes_NNS on_IN infected_JJ human_JJ monocytes_NNS ._SENT We_PP are_VBP equally_RB eager_JJ to_TO determine_VB whether_IN obstructing_VBG the_DT IFN_NP pathway_NN helps_VBZ MV_NP induce_VB and_CC sustain_VB viremia_NN ._SENT PBMC_NN from_IN 10_CD human_JJ donors_NNS were_VBD infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD ,_, and_CC 48_CD h_NN later_RBR ,_, cell_NN surface_NN class_NN II_NP (_( A_NP )_) or_CC class_VB I_PP (_( B_NP )_) complexes_NNS were_VBD measured_VBN by_IN flow_NN cytometric_JJ analysis_NN ._SENT PBMC_NN from_IN 10_CD human_JJ donors_NNS were_VBD infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD ,_, and_CC 48_CD h_NN later_RBR ,_, cell_NN surface_NN class_NN II_NP (_( A_NP )_) or_CC class_VB I_PP (_( B_NP )_) complexes_NNS were_VBD measured_VBN by_IN flow_NN cytometric_JJ analysis_NN ._SENT Mean_JJ fluorescence_NN intensity_NN (_( MFI_NP )_) values_NNS from_IN three_CD independent_JJ experiments_NNS are_VBP shown_VBN ._SENT I-shaped_JJ bars_NNS indicate_VBP standard_JJ deviations_NNS of_IN values_NNS for_IN mock-_NN and_CC Edm-infected_JJ cells_NNS (_( P_NN <_SYM 0.01_CD )_) ._SENT Class_NP II_NP protein_NN levels_NNS in_IN mock-infected_JJ and_CC Edm-infected_JJ cells_NNS were_VBD statistically_RB indistinguishable_JJ ._SENT After_IN infection_NN ,_, significant_JJ differences_NNS in_IN class_NN I_CD protein_NN levels_NNS were_VBD measured_VBN for_IN donors_NNS B_NP ,_, C_NP ,_, D_NP ,_, F_NP ,_, G_NP ,_, and_CC J._NP Ten_CD thousand_CD total_JJ events_NNS were_VBD collected_VBN ._SENT Purified_VBN monocytes_NNS from_IN donors_NNS C_NP and_CC F_NP were_VBD infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD ,_, and_CC 48_CD h_NN later_RBR ,_, surface_NN class_NN I_PP and_CC class_VB II_NP complexes_NNS were_VBD measured_VBN by_IN flow_NN cytometric_JJ analysis_NN ._SENT Purified_VBN monocytes_NNS from_IN donors_NNS C_NP and_CC F_NP were_VBD infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD ,_, and_CC 48_CD h_NN later_RBR ,_, surface_NN class_NN I_PP and_CC class_VB II_NP complexes_NNS were_VBD measured_VBN by_IN flow_NN cytometric_JJ analysis_NN ._SENT Mean_JJ fluorescence_NN intensity_NN (_( MFI_NP )_) values_NNS are_VBP shown_VBN for_IN representative_JJ experiments_NNS done_VBN in_IN duplicate_NN on_IN the_DT same_JJ day_NN ._SENT I_PP bars_VBZ indicate_VB standard_JJ deviations_NNS of_IN values_NNS for_IN mock-_NN and_CC Edm-infected_JJ cells_NNS (_( P_NN <_SYM 0.01_CD )_) ._SENT Ten_CD thousand_CD total_JJ events_NNS were_VBD collected_VBN ._SENT PM_NP (_( A_NP )_) or_CC PBMC_NP (_( B_NP )_) from_IN donors_NNS E_NP and_CC F_NP were_VBD either_RB mock_JJ infected_VBN or_CC infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD for_IN 48_CD h._NP PM_NP (_( A_NP )_) or_CC PBMC_NP (_( B_NP )_) from_IN donors_NNS E_NP and_CC F_NP were_VBD either_RB mock_JJ infected_VBN or_CC infected_VBN with_IN Edm_NP at_IN an_DT MOI_NP of_IN 1_CD for_IN 48_CD h._NN At_IN the_DT time_NN of_IN inoculation_NN ,_, cells_NNS were_VBD treated_VBN or_CC not_RB treated_VBN with_IN 1,000_CD U_NN of_IN IFN-gamma/ml_NP ._SENT Cells_NNS were_VBD analyzed_VBN for_IN surface_NN expression_NN of_IN class_NN I_PP or_CC class_VB II_NP proteins_NNS by_IN flow_NN cytometry_NN ,_, and_CC mean_VB fluorescence_NN intensity_NN (_( MFI_NP )_) values_NNS are_VBP reported_VBN ._SENT Ten_CD thousand_CD total_JJ events_NNS were_VBD collected_VBN ._SENT PM_NN from_IN two_CD donors_NNS were_VBD either_RB treated_VBN or_CC not_RB treated_VBN with_IN UV-inactivated_NP Edm_NP (_( UV-Edm_NP )_) at_IN an_DT MOI_NP of_IN 1_CD for_IN 48_CD h_NN ,_, and_CC some_DT cells_NNS were_VBD simultaneously_RB treated_VBN with_IN IFN-gamma_NP ._SENT PM_NN from_IN two_CD donors_NNS were_VBD either_RB treated_VBN or_CC not_RB treated_VBN with_IN UV-inactivated_NP Edm_NP (_( UV-Edm_NP )_) at_IN an_DT MOI_NP of_IN 1_CD for_IN 48_CD h_NN ,_, and_CC some_DT cells_NNS were_VBD simultaneously_RB treated_VBN with_IN IFN-gamma_NP ._SENT For_IN cells_NNS from_IN each_DT donor_NN ,_, the_DT bars_NNS represent_VBP valu_NN 